In addition, the MG1-GFP oncolytic virus exhibits potent killing activity against human-derived prostate cancer cells (DU145, PC3, LNCaP) and mouse-derived prostate cancer cells (TRAMP-C1, TRAMP-C2); among them, TRAMP-C2 cells are highly sensitive to MG1-GFP at a low multiplicity of infection; in the study of clinical samples, 90% of patients’ biopsy samples can be effectively infected by MG1-GFP, and the yield of the virus in tumor cells is significantly higher than the initial input amount (99). This evidence concerns the gene MUC5B and prostate carcinoma.